Literature DB >> 33670007

Synthesis and Biological Evaluation of Novel 4-(4-Formamidophenylamino)-N-methylpicolinamide Derivatives as Potential Antitumor Agents.

Nana Meng1,2, Shuyan Zhou1, Min Hu3, Youzhi Xu1, Yong Xia1, Xiuxiu Zeng1, Luoting Yu1.   

Abstract

A novel series of 4-(4-formamidophenylamino)-N-methylpicolinamide derivatives were synthesized and evaluated against different tumor cell lines. Experiments in vitro showed that these derivatives could inhibit the proliferation of two kinds of human cancer cell lines (HepG2, HCT116) at low micromolar concentrations and the most potent analog 5q possessed broad-spectrum antiproliferative activity. Experiments in vivo demonstrated that 5q could effectively prolong the longevity of colon carcinoma-burdened mice and slow down the progression of cancer cells by suppression of angiogenesis and the induction of apoptosis and necrosis.

Entities:  

Keywords:  4-(4-formamidophenylamino)-N-methylpicolinamide derivatives; angiogenesis inhibitors; anti-proliferation; apoptosis; pharmacology

Mesh:

Substances:

Year:  2021        PMID: 33670007      PMCID: PMC7926825          DOI: 10.3390/molecules26041150

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  24 in total

Review 1.  Proliferation, cell cycle and apoptosis in cancer.

Authors:  G I Evan; K H Vousden
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.

Authors:  Li Sun; Chris Liang; Sheri Shirazian; Yong Zhou; Todd Miller; Jean Cui; Juri Y Fukuda; Ji-Yu Chu; Asaad Nematalla; Xueyan Wang; Hui Chen; Anand Sistla; Tony C Luu; Flora Tang; James Wei; Cho Tang
Journal:  J Med Chem       Date:  2003-03-27       Impact factor: 7.446

Review 3.  Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions.

Authors:  Sanaullah Sajib; Fatema Tuz Zahra; Michail S Lionakis; Nadezhda A German; Constantinos M Mikelis
Journal:  Angiogenesis       Date:  2017-11-06       Impact factor: 9.596

4.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.

Authors:  P Lindahl; B R Johansson; P Levéen; C Betsholtz
Journal:  Science       Date:  1997-07-11       Impact factor: 47.728

5.  SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Authors:  Zhi-Xing Cao; Ren-Lin Zheng; Hong-Jun Lin; Shi-Dong Luo; Yan Zhou; You-Zhi Xu; Xiu-Xiu Zeng; Zhao Wang; Li-Na Zhou; Yong-Qiu Mao; Li Yang; Yu-Quan Wei; Luo-Ting Yu; Sheng-Yong Yang; Ying-Lan Zhao
Journal:  Cell Physiol Biochem       Date:  2011-06-15

6.  Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.

Authors:  Jing Wen; A-fu Fu; Li-Juan Chen; Xing-Jiang Xie; Guang-Li Yang; Xian-Cheng Chen; Yong-Sheng Wang; Jiong Li; Ping Chen; Ming-Hai Tang; Xi Ming Shao; You Lu; Xia Zhao; Yu-Quan Wei
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

7.  Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.

Authors:  Michele H Potashman; James Bready; Angela Coxon; Thomas M DeMelfi; Lucian DiPietro; Nicholas Doerr; Daniel Elbaum; Juan Estrada; Paul Gallant; Julie Germain; Yan Gu; Jean-Christophe Harmange; Stephen A Kaufman; Rick Kendall; Joseph L Kim; Gondi N Kumar; Alexander M Long; Seshadri Neervannan; Vinod F Patel; Anthony Polverino; Paul Rose; Simon van der Plas; Douglas Whittington; Roger Zanon; Huilin Zhao
Journal:  J Med Chem       Date:  2007-08-15       Impact factor: 7.446

8.  Novel microtubule-interacting phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy.

Authors:  Ravi Kumar Anchoori; Madeleine Susanne Quirine Kortenhorst; Manuel Hidalgo; Taradas Sarkar; Gurulingappa Hallur; Ruoli Bai; Paul J Van Diest; Ernest Hamel; Saeed R Khan
Journal:  J Med Chem       Date:  2008-09-09       Impact factor: 7.446

9.  Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.

Authors:  Yujia Dai; Kresna Hartandi; Zhiqin Ji; Asma A Ahmed; Daniel H Albert; Joy L Bauch; Jennifer J Bouska; Peter F Bousquet; George A Cunha; Keith B Glaser; Christopher M Harris; Dean Hickman; Jun Guo; Junling Li; Patrick A Marcotte; Kennan C Marsh; Maria D Moskey; Ruth L Martin; Amanda M Olson; Donald J Osterling; Lori J Pease; Niru B Soni; Kent D Stewart; Vincent S Stoll; Paul Tapang; David R Reuter; Steven K Davidsen; Michael R Michaelides
Journal:  J Med Chem       Date:  2007-03-08       Impact factor: 7.446

Review 10.  Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Authors:  David L Deremer; Celalettin Ustun; Kavita Natarajan
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.